Recent Findings Beyond weight reduction, GLP-1RAs have shown positive cardiovascular outcomes in patients with elevated ASCVD risk, heart failure with preserved ejection fraction, obstructive sleep apnea, blood pressure, and dyslipidemia
Liraglutide, a human GLP-1 analogue, significantly improves beta cell function in subjects with type 2 diabetes
From then to now Although they have surged in demand (and public awareness) across the past couple of years, GLP-1s have actually been around for several decades at this point
Some people continue to experience mild appetite changes long-term, which is actually part of how the medication supports weight management
The appetite suppression continues providing therapeutic benefit while the unpleasant gastrointestinal symptoms resolve